Lupin Receives Approval from U.S. FDA for Brivaracetam Tablets

India

healthysoch

Mumbai, Baltimore, December 21, 2022:

loading...

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, a generic equivalent of Briviact® Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, of UCB Inc. The product will be manufactured at Lupin’s facility in Nagpur, India.

Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, (RLD Briviact®) had estimated annual sales of USD 420 million in the U.S. (IQVIA MAT September 2022).

healthysoch

healthy soch

healthysoch.com is an online Health Portal. This platform provides valuable health information for managing health, better lifestyle & support to those who seek information on health issues. Our contents are timely and credible. healthysoch.com is a growing web portal with many columnists & writers contributing from all over India.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Previous Story

Glenmark Pharmaceuticals Limited (Glenmark),launched the first triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India

Next Story

Lupin Diagnostics Expands its Footprint in Central India

Latest from General